Precursor Cell Lymphoblastic Leukemia-Lymphoma
"Precursor Cell Lymphoblastic Leukemia-Lymphoma" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A neoplasm characterized by abnormalities of the lymphoid cell precursors leading to excessive lymphoblasts in the marrow and other organs. It is the most common cancer in children and accounts for the vast majority of all childhood leukemias.
Descriptor ID |
D054198
|
MeSH Number(s) |
C04.557.337.428.600 C15.604.515.560.600 C20.683.515.528.600
|
Concept/Terms |
Precursor Cell Lymphoblastic Leukemia-Lymphoma- Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Precursor Cell Lymphoblastic Leukemia Lymphoma
- Leukemia, Acute Lymphoblastic
- Acute Lymphoblastic Leukemia
- Leukemia, Lymphoblastic
- Leukemia, Lymphoblastic, Acute
- Leukemia, Lymphocytic, Acute
- Lymphoblastic Leukemia
- Lymphoblastic Leukemia, Acute
- Lymphoblastic Lymphoma
- Lymphocytic Leukemia, Acute
- Acute Lymphocytic Leukemia
- Leukemia, Acute Lymphocytic
- Lymphoma, Lymphoblastic
- Acute Lymphoid Leukemia
- Leukemia, Acute Lymphoid
- Lymphoid Leukemia, Acute
- Leukemia, Lymphoid, Acute
Leukemia, Lymphocytic, Acute, L1- Leukemia, Lymphocytic, Acute, L1
- Lymphocytic Leukemia, L1
- L1 Lymphocytic Leukemia
- Leukemia, L1 Lymphocytic
- Lymphoblastic Leukemia, Acute, Childhood
- Lymphoblastic Leukemia, Acute, L1
- ALL, Childhood
- Childhood ALL
- Leukemia, Lymphoblastic, Acute, L1
Leukemia, Lymphocytic, Acute, L2- Leukemia, Lymphocytic, Acute, L2
- Lymphocytic Leukemia, L2
- L2 Lymphocytic Leukemia
- Leukemia, L2 Lymphocytic
- Lymphoblastic Leukemia, Acute, Adult
- Lymphoblastic Leukemia, Acute, L2
- Leukemia, Lymphoblastic, Acute, L2
- Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
|
Below are MeSH descriptors whose meaning is more general than "Precursor Cell Lymphoblastic Leukemia-Lymphoma".
Below are MeSH descriptors whose meaning is more specific than "Precursor Cell Lymphoblastic Leukemia-Lymphoma".
This graph shows the total number of publications written about "Precursor Cell Lymphoblastic Leukemia-Lymphoma" by people in this website by year, and whether "Precursor Cell Lymphoblastic Leukemia-Lymphoma" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 21 | 5 | 26 |
1995 | 16 | 5 | 21 |
1996 | 13 | 3 | 16 |
1997 | 9 | 4 | 13 |
1998 | 14 | 3 | 17 |
1999 | 15 | 2 | 17 |
2000 | 22 | 0 | 22 |
2001 | 17 | 5 | 22 |
2002 | 12 | 1 | 13 |
2003 | 15 | 4 | 19 |
2004 | 13 | 5 | 18 |
2005 | 20 | 3 | 23 |
2006 | 23 | 4 | 27 |
2007 | 24 | 3 | 27 |
2008 | 23 | 6 | 29 |
2009 | 21 | 6 | 27 |
2010 | 33 | 9 | 42 |
2011 | 33 | 8 | 41 |
2012 | 32 | 1 | 33 |
2013 | 43 | 3 | 46 |
2014 | 37 | 2 | 39 |
2015 | 44 | 2 | 46 |
2016 | 42 | 3 | 45 |
2017 | 37 | 6 | 43 |
2018 | 45 | 3 | 48 |
2019 | 53 | 1 | 54 |
2020 | 54 | 2 | 56 |
2021 | 53 | 1 | 54 |
2022 | 56 | 0 | 56 |
2023 | 54 | 1 | 55 |
2024 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Precursor Cell Lymphoblastic Leukemia-Lymphoma" by people in Profiles.
-
A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia. Blood Adv. 2024 Feb 27; 8(4):909-915.
-
Enhanced Risk Stratification for Children and Young Adults with B-Cell Acute Lymphoblastic Leukemia: A Children's Oncology Group Report. Leukemia. 2024 Apr; 38(4):720-728.
-
Single agent subcutaneous blinatumomab for advanced acute lymphoblastic leukemia. Am J Hematol. 2024 Apr; 99(4):586-595.
-
Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission. Blood. 2024 Feb 01; 143(5):417-421.
-
Myeloid lineage switch in KMT2A-rearranged acute lymphoblastic leukemia treated with lymphoid lineagedirected therapies. Haematologica. 2024 Jan 01; 109(1):293-297.
-
Dose-Dense Mini-Hyper-CVD, Inotuzumab Ozogamicin and Blinatumomab Achieves Rapid MRD-Negativity in Philadelphia Chromosome-Negative B-cell Acute Lymphoblastic Leukemia. Clin Lymphoma Myeloma Leuk. 2024 04; 24(4):e168-e173.
-
Prognostic significance of ETP phenotype and minimal residual disease in T-ALL: a Children's Oncology Group study. Blood. 2023 12 14; 142(24):2069-2078.
-
Concordance of Next-Generation Sequencing and Multiparametric Flow Cytometry Methods for Detecting Measurable Residual Disease in Adult Acute Lymphoblastic Leukemia: Optimizing Prediction of Clinical Outcomes From a Single-Center Study. Clin Lymphoma Myeloma Leuk. 2024 03; 24(3):e59-e66.e2.
-
HyperCVAD versus pegaspargase-containing regimens for Hispanic adults with newly diagnosed B-cell acute lymphoblastic leukemia. Eur J Haematol. 2024 Mar; 112(3):392-401.
-
Blinatumomab Therapy Is Associated with Favorable Outcomes after Allogeneic Hematopoietic Cell Transplantation in Pediatric Patients with B Cell Acute Lymphoblastic Leukemia. Transplant Cell Ther. 2024 Feb; 30(2):217-227.